Hello everyone,
I have question about Locke's method for bioequivalence evaluation of topical dermtologic corticosteroids that is suggested by FDA. It described in the guidance (check attached file) in appendix V on pages 38-39. Maybe someone had experience with it? How it can be realised in Phoenix Winnonlin?
Best regards, Veronika.
Attached Files
Edited by Simon Davis, 23 November 2018 - 09:26 AM.